News Releases 2001

The following information was accurate at the time of posting, but may be superceded by subsequent disclosure.

Dec 06, 2001
Inex files final prospectus

Dec 05, 2001
INEX added to TSE 300

Nov 27, 2001
INEX files preliminary prospectus

Nov 22, 2001
Inex announces $40.0 M bought deal financing

Nov 20, 2001
Inex signs agreement with GlaxoSmithKline

Nov 19, 2001
Inex Corporate Partnership Conference Call

Nov 13, 2001
Clinical development of Onco TCS to include combination therapy with Etoposide

Nov 07, 2001
INEX Third Quarter Results

Sep 20, 2001
Inex Publishes OligoVax Data

Sep 06, 2001
Inex's spin-off Protiva Biotherapeutics signs $14.5 M Financing

Sep 05, 2001
Clinical development of Onco TCS to include combination therapy with Rituxan®

Aug 13, 2001
Data Safety Monitoring Board recommends continuation of pivotal Phase II/III clinical trial

Jul 26, 2001
Inex Q2 results and Q3/Q4 milestones

Jul 23, 2001
Inex completes enrollment in INX-3280 clinical trial

Jul 19, 2001
Q2 Conference Call Notification (Upcoming Webcast July 26,2001)

May 16, 2001
Inex Releases First Quarter Results

Apr 30, 2001
Inex Forms Joint Venture with Elan

Apr 11, 2001
Inex Releases 2000 Operating Results & 2001 Milestones

Mar 28, 2001
Inex Reports to the American Association of Cancer Research New Vaccine Delivery Technology to Treat Cancer

Mar 26, 2001
Inex Begins Phase II Clinical Trial to Evaluate Onco TCS as a First-Line Treatment for Non-Hodgkin's Lymphoma

Jan 31, 2001
Inex Pharmaceuticals' Onco TCS Pivotal Clinical Trial Initiated at US Oncology Community Cancer Centers

Jan 24, 2001
Inex Pharmaceuticals Creates New Company to compete in Fast-Growing Therapeutic Protein Marketplace.
Protiva Biotherapeutics will develop cancer and inflammation drugs using proprietary gene-delivery technology